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ABSTRACT 
Background & Aims: It is a challenge to manage patients with ulcerative proctitis (UP) 
refractory to standard therapy. We investigated the effectiveness of tumor necrosis factor 
(TNF) antagonists in a large cohort of patients with refractory UP. 
Methods: We conducted a nationwide retrospective cohort study of 104 consecutive 
patients with active UP refractory to conventional therapies, treated at 1 of 15 centers in 
France or 1 center in Belgium (the GETAID cohort). Patients received at least 1 injection of 
anti-TNF (infliximab, adalimumab, golimumab) from October 2006 through February 2017. 
Clinical response was defined as significant improvement in UC-related symptoms, and 
remission as complete disappearance of UC-related symptoms, each determined by treating 
physicians. We collected demographic, clinical, and treatment data. The median duration of 
follow-up was 24 months (interquartile range, 13–51 months). The primary outcome was 
clinical response of UP to anti-TNF treatment. 
Results: : Overall, 80 patients (77%) had a clinical response to anti-TNF therapy and 52 
patients (50%) achieved clinical remission. Extra-intestinal manifestations (odds ratio [OR], 
0.24; 95% CI, 0.08–0.7), ongoing treatment with topical steroids (OR, 0.14; 95% CI, 0.03–
0.73), and ongoing treatment with topical 5-aminosalycilates (OR, 0.21; 95% CI, 0.07–0.62) 
were significantly associated with the absence of clinical remission. Sixty percent (38/63) of 
the patients who had endoscopic assessment during follow up had mucosal healing. Among 
the overall population (n=104), the cumulative probabilities of sustained clinical remission 
were 87.6%±3.4% at 1 year and 74.7%±4.8% at 2 years. 
Conclusion: In a retrospective study of 104 patients with refractory UP, anti-TNF therapy 
induced clinical remission in 50% and mucosal healing in 60%. About two thirds of the 
patients were still receiving anti-TNF therapy at 2 years. 
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INTRODUCTION 
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by 
intestinal inflammation limited to the colonic mucosa.[1] In population-based studies, 25–
55% of patients had ulcerative proctitis (UP) at diagnosis.[2] UP defined as a disease limited 
to the rectum is classified as E1 according to the Montreal classification.[3] Although it is 
generally assumed that UP represents the benign end of the spectrum of UC, it is responsible 
for many distressing symptoms including increased stool frequency, tenesmus, urgency and 
bleeding, and clearly alters patients’ quality of life.[2] Despite the significant benefits of 
aminosalicylates and corticosteroids, some patients with UP fail to improve and will require 
additional medical therapy.  
Medical management of patients with UP refractory to standard therapies is challenging as 
there is very little evidence-based data regarding drug efficacy in this clinical situation.[4] 
Several medications have been tested to treat refractory UP.[5] In a randomized controlled 
trial, azathioprine (AZA) was more effective than oral 5-aminosaliylates (5-ASA) to achieve 
steroid-free clinical and endoscopic remission.[6] Cyclosporin enemas and oral methotrexate 
have not proven to be significantly effective in inducing and maintaining long-term clinical 
response and remission.[6-8] A recent randomized, placebo-controlled, trial demonstrated 
that tacrolimus rectal ointment was more effective than placebo for the induction of clinical 
remission and mucosal healing (MH) in patients with UP.[9] Appendectomy has also been 
proposed as a treatment for patients with refractory UP.[10] Overall, these results remain 
difficult to interpret because of small sample size and the lack of well-designed published 
studies supporting their efficacy for refractory UP. 
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Furthermore, patients with UC limited to the rectum are systematically excluded from 
randomized clinical trials on biologics. Topical administration of infliximab was found to be 
effective in one patient with chronic refractory UP.[11] Only one French small retrospective 
observational study has investigated the efficacy of infliximab in patients with refractory 
UP.[12] Regarding short-term outcome, 69% (9/13) patients presented a complete response 
to infliximab. To date, there is no data regarding efficacy of adalimumab, golimumab or 
other biologics in patients with refractory UP.  
The aim of this study was therefore to evaluate the effectiveness of anti-TNF therapy in a 
large nationwide retrospective cohort study from the GETAID.   
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METHODS 
Selection of patients 
A retrospective observational study was performed in 15 French and one Belgium referral 
center affiliated with the Groupe d'Etude Thérapeutique des Affections Inflammatoires du 
tube Digestif (GETAID). All consecutive patients with a diagnosis of UC based on clinical, 
biological and morphological criteria according to European guidelines, and with an active 
UP according to treating physician (maximal extension of macroscopic endoscopic lesions 
<20 cm from the anal verge) refractory to conventional therapies (topical and oral 5-ASA, 
topical and systemic corticosteroids and/or thiopurines) who were treated with at least one 
injection of a monoclonal anti-TNFα antibody (infliximab, adalimumab, golimumab) from 
October 2006 to February 2017 were included in the study. The study protocol was 
approved by the Montpellier University institutional review board. All authors had access to 
the study data, reviewed and approved the final manuscript. 
Data collection 
The date of inclusion corresponded to the first administration of anti-TNF therapy. Patient 
files were retrospectively reviewed and demographic, biological, and endoscopic data were 
obtained from the medical records. The following characteristics were anonymously 
recorded for each included patient: gender, age at inclusion, date of diagnosis, duration of 
disease, smoking status, presence of extraintestinal manifestations, prior exposure to UC 
treatment including local and systemic steroids, local and oral 5-ASA, conventional 
immunosuppressants (thiopurines, methotrexate and cyclosporin), UP clinical activity before 
the start of anti-TNF based on Mayo clinical subscore (from 0 to 9) and endoscopic findings 
(Mayo endoscopic subscore and UCEIS) when available, main indication for introducing anti-
TNF, type of anti-TNF (infliximab, adalimumab, golimumab), anti-TNF induction and 
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maintenance doses, type of response (no response, partial response and complete 
response), concomitant treatment with thiopurines, other ongoing drugs at commencement 
of anti-TNF, duration of anti-TNF treatment, optimization of the treatment, C-reactive 
protein levels (CRP) and endoscopic findings at inclusion and during follow-up. All data were 
encoded in an Excel® electronic database which was anonymized with attribution of a 
nonsignificant number for each patient.  
Outcomes 
The primary objective was to assess the primary clinical response of UP to anti-TNF 
treatment. Evaluation of the global clinical response to anti-TNF was based on the 
judgement of the referring physician and was graded as follows: no response, clinical 
response, and clinical remission. Clinical response was defined as significant improvement in 
UC-related symptoms as judged by the treating physician. Remission was defined as the 
complete disappearance of UC-related symptoms as judged by the treating physician. 
Clinical outcomes were collected by each local investigators from retrospective notes in each 
patient chart. Definitions of primary outcomes were clearly defined in study protocol and 
explained to each local investigator before data collection.  Secondary outcomes were: (1) 
clinical response and remission during the induction phase (first 3 months), (2) changes in 
the Mayo clinical subscore (retrospectively calculated from physician notes) between anti-
TNF therapy initiation and week 12, (3) Mucosa healing during follow-up  (defined as a Mayo 
endoscopic subscore of 0 or 1) among patients who underwent endoscopic assessment, (4) 
changes in the Mayo endoscopic subscore or UCEIS index prospectively  assessed before 
anti-TNF initiation and during the first follow-up colonoscopy, (5) coloproctectomy during 
follow-up, (6) the identification of predictive factors of anti-TNF efficacy, (6) the cumulative 
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probability of anti-TNF retention among primary responders, and (7) the safety of anti-TNF 
treatment. The rate of anti-TNF optimization was also recorded, but was not considered to 
be a loss of clinical benefit. To determine safety, all adverse events, defined as any 
significant event that occurred from the date of inclusion to the last follow-up, were 
recorded in patients receiving at least one injection of any anti-TNF agents. Severe adverse 
events were defined as any adverse event that resulted in hospitalization or extension of the 
hospital stay, was fatal or life threatening, or led to a significant disability. 
 
Statistical analysis 
Descriptive statistics were used to analyze baseline characteristics. Medians with 
interquartile ranges (IQR) or means with standard deviations (SD) were calculated for 
continuous data, and percentages were computed for discrete data. Univariate and 
multivariate logistic regression were performed to identify predictive factors associated to 
clinical remission with anti-TNF treatment, expressed as odds ratios (OR) with 95% 
confidence intervals (CI). Variables with a p value below 0.1 were used for multivariate 
analysis. For multivariate analysis adjusted for sex and age at diagnosis, variables included 
were extraintestinal manifestations, the type of anti-TNF (subcutaneous vs intravenous), 
concomitant thiopurines, ongoing treatment with topical 5-ASA and topical steroids. 
Proportion of patients with sustained clinical remission and anti-TNF failure (defined as the 
occurrence of anti-TNF withdrawal for loss of response or intolerance and/or colectomy) 
over time were described using Kaplan-Meier survival analysis. A p value of < 0.05 was 
considered to be significant. 
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RESULTS 
Patient characteristics  
One-hundred and four patients (51 female and 53 male) with refractory UP treated with 
anti-TNFα from 16 GETAID centers were included in the study, with a median follow-up of 24 
(IQR: 12.9-51.2) months. The baseline demographic and clinical characteristics of the 
patients are presented in table 1. Mean age at diagnosis was 34±11.9 years. Anti-TNF 
therapy was started after a median follow-up of 46 (IQR:19.8-110.5) months from the 
diagnosis of UP.  
Fifty percent (52/104) of the patients were treated with infliximab, 39% (41/104) with 
adalimumab and 11% (11/104) with golimumab. Fifty-three (55/104) percent of patients 
were concomitantly treated with topical or oral 5-ASA or steroids at the start of anti-TNF 
therapy. Anti-TNF was associated with a thiopurine in 38 % (40/104) of the patients. Patients 
were initially treated with the recommended dose of anti-TNF for induction. Following 
initiation of anti-TNF, 47% (49/104) of patients had an intensification of the anti-TNF agent 
after a median duration of follow-up of 6 (IQR: 3-13.6) months; 17 patients had a dose 
increase, 24 a shortening of the injection interval, and 8 both dose increase and interval 
shortening. 
Short-term outcomes 
Following a median duration of follow-up of 3 (IQR:1.6-7.0) months between anti-TNF 
initiation and clinical evaluation, 77% (80/104) of patients had a primary clinical response to 
the anti-TNF agent and 50% (52/104) achieved clinical remission (Figure 1). Corticosteroid-
free remission was achieved in 45% (n=47/104) of the patients. The mean Mayo clinical 
subscore before the start of anti-TNFα was of 5.9 ± 1.9 points (n=99). At 3 months after anti-
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TNF start 42% (33/78) of the patients had a MAYO clinical subscore < 2. In patients with 
clinical scores available at baseline and 3 months after anti-TNFα start (n = 76), we observed 
a significant decrease in the Mayo clinical subscore (5.9 ± 1.9 vs. 2.5 ± 2.6, p < 0.001) 
between baseline and week 12 evaluation and 58% of the patients presented at least a 
clinical response defined by a decreased in the Mayo clinical subscore of 3 or more points 
with bleeding score of 0 or 1. Among patients with an available CRP at baseline and 3 
months after anti-TNF treatment initiation (n=49), there was a significant decrease in the 
mean CRP level (11.6±21.4 at inclusion vs. 4.7±4.6 at the end of the anti-TNF induction 
period, p=0.028) (Supplementary Table 1). 
Factors associated with short-term outcomes 
In univariate analysis, extraintestinal manifestations, ongoing topical steroids at baseline and 
ongoing topical 5-ASA at baseline were significantly associated with the absence of primary 
clinical remission (Table 2). Concomitant treatment with thiopurines at baseline was 
significantly associated with primary clinical remission (Table 2). In a multivariate analysis 
adjusted for sex and age at diagnosis and including as variables extraintestinal 
manifestations, the type of anti-TNF (subcutaneous vs intravenous), concomitant 
thiopurines, ongoing treatment with topical 5-ASA and topical steroids, extraintestinal 
manifestations (OR=0.24; 95%CI:0.08-0.7; p=0.009), ongoing topical steroids at baseline 
(OR=0.14; 95%CI:0.03-0.73; p=0.019) and ongoing topical 5-ASA at baseline (OR=0.21; 
95%CI:0.07-0.62; p=0.007) were independently associated with the absence of primary 
clinical remission (Table 2). 
Endoscopic findings  
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A baseline colonoscopy was available in 82% (85/104) patients with a median delay before 
anti-TNF start of 0.9 (IQR: 0.1-2.16) months. A follow-up colonoscopy was available in 61% 
(63/104) of patients after a median follow-up of 11.7 (IQR: 5.5-17.4) months. Among these 
patients, 60% (38/63) had mucosal healing (Mayo endoscopic subscore of 0 or 1) (Figure 1). 
Among these patients, there was a significant decrease in the Mayo endoscopic subscore 
(2.4±0.6 vs. 1.3±1.1, n=46, p<0.001) and in the UCEIS index (4.9±1.4 vs. 2.3±2.3, n=42, 
p<0.001), between baseline and follow-up colonoscopies (Supplementary Table 1).   
Long-term outcomes 
Among the overall population (n=104), after a median follow-up of 23.6 months (IQR:12.9-
57.9), 64% (67/104) were in clinical remission at last follow up. Among these 104 patients, 
the cumulative probability of sustained clinical remission was 87.6%±3.4% at one year, 
74.7%±4.8% at two years, and 56.4%±6.2% at 5 years (Figure 2a). When considering only 
patients with an initial response to anti-TNF therapy (n=80), the cumulative probability of 
sustained clinical remission, irrespective of the treatment given, was 90.5%±3.4% at one 
year, 77.9%±5.3% at two years, and 55.8%±7.4% at five years (Figure 2b). During follow-up, 
9% (9/104) of patients were hospitalized for a flare of their UP and 4% (4/104) underwent a 
coloproctectomy with ileal pouch-anal anastomosis. 
Among the 24 patients with primary non response to anti-TNFα, 75% (18/24) of the patients 
were switch to another ant-TNFα agent and 46% (11/24) were eventually treated with 
vedolizumab with achievement of clinical remission in 22% (4/18) and 82% (9/11) of the 
cases, respectively. Among patients with an initial response to anti-TNFα, 19% (15/80) had a 
switch to another anti-TNFα and 11% (9/80) were eventually treated with vedolizumab 
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during follow-up with achievement of clinical remission in 53% (8/15) and 56% (5/9) of the 
cases, respectively. 
At the end of the follow-up period, 61% (63/104) of the patients were still on anti-TNF at last 
follow up. Among the 80 patients with a primary clinical response to anti-TNF, 34% (27/80) 
stopped the first anti-TNF agent for secondary loss of response, intolerance or surgery. In 
these patients (n=80), the cumulative probability of first anti-TNF failure-free survival (no 
withdrawal for secondary loss of response, intolerance and/or surgery) was 94.6%±2.6% at 6 
months, 80.6%±4.9% at one year, and 69.6%±5.9% at two years. Optimization of anti-TNF 
therapy during follow-up was performed in 43.7% of the patients (35/80). Failure of first 
anti-TNF therapy defined as optimization, intolerance, loss of response or surgery was 
observed in 57.5% (46/80) of the patients during follow-up.  
Safety of anti-TNF therapy 
There were missing data for 8 patients. Overall, 22% (21/96) of the patients presented side 
effects after starting anti-TNF therapy (Table 3). Three patients had an infusion reaction 
leading to anti-TNF withdrawal, five patients had skin manifestations, four patients had an 
infection, one patient presented alopecia, and 9 patients had other side effects such as 
arthralgia, headache, abnormal liver enzymes or weight gain.      
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DISCUSSION 
The management of refractory UP remains challenging in the era of biologics. These patients 
are excluded from clinical trials on biologics and available studies on the effectiveness of 
anti-TNF therapy in a real-life setting are of small sample size.[12] As UP represents about 
one third of all cases of UC, 5-ASA treatment is often insufficient in moderate to severe UC 
and azathioprine has modest efficacy in this indication.[13] Further evidence regarding the 
potential of anti-TNF therapy in treating these patients is eagerly awaited.   
We first demonstrated that anti-TNF therapy, either intravenously or subcutaneously, can 
induce a clinical response in 77% of patients. These results are in line with previous reports. 
Indeed, in a small retrospective study on infliximab efficacy in patients with UP, 85% of 
patients experienced clinical improvement.[12] The ACT (infliximab), ULTRA (adalimumab), 
and golimumab (PURSUIT) trials in patients with pancolitis or left-sided colitis treated with 
infliximab demonstrated short-term clinical response in about 63%–69% of patients 
whatever disease extension.[14-16] Moreover, in our study, clinical response was 
accompanied by a significant drop in CRP levels. Similar changes were in CRP levels were 
reported in the previous retrospective study on infliximab in patients with UP.[12] 
Interestingly, no difference in clinical efficacy was observed in our study between the three 
anti-TNF for patients with UP, as it has already been demonstrated in population-based 
studies and network meta-analysis for patients with UC.[17] Importantly, UP patients 
treated with anti-TNF in our study are truly refractory patients with previous use of topical 
and oral 5-ASA and corticosteroids in a large majority of patients and previous failure of 
thiopurines in almost two thirds of them.  
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Few studies have investigated other immunosuppressants to treat patient with UP. A recent 
retrospective multicenter study assessing the efficacy of AZA in patients with refractory UP 
demonstrated that 71% (10/14) of patients achieved short term response and 21% (3/14) 
steroid-free clinical remission. Also, In this study, after a median follow-up of 46.2 (26.4–
47.8) months, only 5 patients receiving AZA out of 25 had treatment success at the end of 
follow-up.[13] Another multicenter, randomized, double-blind, placebo-controlled, induction 
trial compared the efficacy of a tacrolimus rectal ointment (3ml of tacrolimus at 0.5mg/ml) 
administrated twice a day for 8 weeks with rectal placebo in patients (n=21) with refractory 
UP. In this study, 73% (8/11) of the patients treated with tacrolimus achieved clinical 
response. Clinical remission and mucosal healing were achieved in 45% and 73% of the 
patients treated with tacrolimus.[9] 
It is well established that anti-TNF agents are able to induce mucosal healing in patients with 
UC.[18] Mucosal healing is associated with better outcomes  and is now a therapeutic goal in 
our practice.[18] In our study, we observed mucosal healing (Mayo endoscopic subscore of 0 
or 1) in 60% of the patients with available endoscopic assessment. Moreover, there was a 
significant decrease in the Mayo endoscopic subscore and UCEIS from baseline to follow-up 
colonoscopies. ACT 1 and 2 studies reported the same rate of mucosal healing at week 8 in 
patents with UC treated with infliximab 5mg/kg (62% and 60%, respectively).[14] The 
previous retrospective study on infliximab in 13 patients with UP reported mucosal healing 
in only two of the seven patients (28%) with follow-up colonoscopies.[12] 
Long-term follow-up is required to assess the sustained efficacy of medical treatment in 
refractory UP. The median follow-up in our study was 24 months. In patients with an initial 
response to anti-TNF, the probability of first anti-TNF failure-free survival at two years was 
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70%. More importantly, among the whole cohort, at the end of the follow-up, 64% of the 
patients with refractory UP were in clinical remission, with 61% still receiving an anti-TNF 
agent. These data are in accordance with previous studies on the long-term outcome of 
patients treated with infliximab for refractory UC, with a sustained clinical response rate of 
68% after  a median follow-up of 33 months.[19] 
Previous studies have identified several clinical or biological factors influencing response to 
anti-TNF in UC, such as severity of the disease, younger age, duration of colitis or extensive 
colitis.[20] In our study, we found that extraintestinal manifestations, ongoing topical 
steroids and 5-ASA at baseline were significantly associated with the absence of clinical 
remission in patients with refractory UP. Another recent study also identified extraintestinal 
manifestation as a risk factors for colectomy in patients with UC on thiopurine 
treatment.[21] In our cohort combination therapy with thiopurines was associated with 
clinical remission in univariate analysis only, probably because of lack  of statistical power. 
Regarding ongoing treatment with topical 5-ASA or steroids, this may emphasize that the 
fact that patients on topical treatments at anti-TNF initiation might present more refractory 
UP.  
In the first retrospective study on UP, only one patient relapsed after infliximab induction 
and underwent proctocolectomy.[12] In our cohort, 4% of patients underwent 
proctocolectomy with ileo-anal anastomosis. This colectomy rate is lower than those 
reported in patients with left-sided or extensive UC (17%), as expected given the limited 
disease extent.[19] Very little is known about the switch to another anti-TNF agent in 
patients with refractory UP. Our cohort provides interesting data showing that more than 
two thirds of the patients with anti-TNF primary non-response were switched to a second 
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anti-TNF during follow-up with achievement of clinical remission in 22% of the cases. 
Moreover, half of these patients eventually received vedolizumab during follow-up with 
achievement of clinical remission in 82% of patients.  
The strengths of our study are the large number of patients included, the nationwide 
character of the study and the duration of follow-up which allowed us to look at predictors 
of short and long-term efficacy. Moreover, the availability of data on CRP, an objective 
biomarker of intestinal inflammation, improved the strength of the assessment of anti-TNF 
efficacy in these patients. Limitations of our study are its retrospective character with 
absence of comparator group and the absence of systematic assessment of mucosal healing. 
Moreover, we were not able to collect data on fecal calprotectin, anti-TNF trough level or 
disease extension during follow-up.  
In conclusion, our data support the use of anti-TNF monoclonal antibodies in patients with 
refractory UP with 50% of patients achieving clinical remission and 64% showing sustained 
clinical remission at the end of follow-up. Moreover, our study also demonstrated that anti-
TNF agents are able to induce mucosal healing in 60% of patients with refractory UP. 
Regarding follow-up, about half of the patients were still on anti-TNF therapy at 2 years. 
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TABLES AND FIGURE LEGENDS 
Table 1: Baseline characteristics of patients with refractory ulcerative proctitis  
 n = 104 
Gender, n, %   
Female 51 (49) 
Mean age at diagnosis, years ± SD 34 ± 11.9 
Median duration of disease prior to anti-TNF, years (IQR:1-3) 46 (19.8 – 110.5) 
Active smokers, n, % 6 (6) 
Extraintestinal manifestations, n, %  
Arthralgia and ankylosing spondylitis 24 (23) 
Skin or mucosal lesions 3 (3) 
Uveitis 1 (0.9) 
UC treatment prior to anti-TNF, n, %  
Topical 5-ASA 100 (96) 
Oral 5-ASA 99 (95) 
Topical corticosteroids 85 (82) 
Oral corticosteroids 89 (86) 
Thiopurines 63 (62) 
Methotrexate 9 (9) 
Cyclosporine 5 (5) 
Tacrolimus 0 (0) 
Mean Mayo clinical subscore prior to anti-TNF, ± SD 5.9 ± 1.9 
Mayo endoscopic subscore prior to anti-TNF, n, % (n=88)  
Mayo 1 6 (7) 
Mayo 2 45 (51) 
Mayo 3 36 (41) 
Mean UCEIS endoscopic index prior to anti-TNF, ± SD 4.9 ± 1.4 
Type of anti-TNF n, %  
IFX 52 (50) 
ADA 41 (39) 
GOL 11 (11) 
Reasons for anti-TNF, n, %  
Steroid-dependency 23 (22) 
Failure of corticosteroids 27 (26) 
Failure of immunosuppressant drugs 49 (47) 
Other reasons 7 (7) 
Concomitant therapies, n, %  
Thiopurines 40 (38) 
Methotrexate 7 (7) 
Topical 5-ASA 26 (25) 
Oral 5-ASA 16 (15) 
Topical corticosteroids 15 (14) 
Oral corticosteroids 26 (25) 
Abbreviations: 5-ASA, 5-aminosalycilates; ADA, adalimumab ; Anti-TNF, anti-tumor necrosis factor alpha 
monoclonal antibodies; GOL, golimumab ; IFX, infliximab ; IQR, interquartile range; n, number of patients;  
UC, ulcerative colitis; UCEIS, ulcerative colitis endoscopic index of severity.  
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Table 2: Predictive factors associated with primary clinical remission in patients with ulcerative proctitis treated with 
anti-TNF (n=104) 
  Univariate analysis Multivariate analysis
α
 
Variables  OR 95% CI P-value OR 95% CI P-value 
Sex F vs M 1.471 0.679 3.185 0.327     
Age at diagnosis  Years 0.977 0.945 1.011 0.181     
Smoking Yes vs No 0.458 0.080 2.627 0.381     
Extraintestinal manifestations  Yes vs No 0.316 0.123 0.809 0.016 0.235 0.079 0.701 0.009 
Previous treatments          
Local steroids Yes vs No 1.341 0.483 3.729 0.573     
Systemic steroids Yes vs No 0.838 0.261 2.692 0.767     
Local 5-ASA  Yes vs No 3.187 0.320 31.705 0.323     
Oral 5-ASA  Yes vs No 0.327 0.033 3.249 0.340     
Thiopurines Yes vs No 1.158 0.521 2.575 0.719     
Methotrexate Yes vs No 0.783 0.198 3.098 0.728     
Cyclosporine Yes vs No 4.167 0.449 38.626 0.209     
Mayo clinical subscore at 
baseline 
 1.016 0.821 1.258 0.883     
Type of anti-TNF SC vs IV 0.538 0.247 1.171 0.118     
 ADA vs IFX 0.633 0.278 1.444 0.277     
 GOL vs IFX 0.275 0.065 1.157 0.078     
Duration of disease prior to 
anti-TNF 
Months 1.000 0.997 1.002 0.908     
Combination therapy with 
thiopurines 
Yes vs No 2.284 1.016 5.133 0.046     
Ongoing drugs at anti-TNF start           
Local steroids Yes vs No 0.115 0.024 0.541 0.006 0.142 0.028 0.729 0.019 
Oral steroids Yes vs No 0.410 0.161 1.044 0.062     
Local 5-ASA Yes vs No 0.195 0.070 0.547 0.002 0.211 0.069 0.648 0.007 
Oral 5-ASA Yes vs No 0.722 0.245 2.126 0.555     
α
 Variables included in the multivariate analysis are sex, age at diagnosis, extraintestinal manifestations, type of anti-TNF 
(subcutaneous vs intravenous), concomitant thiopurines, ongoing treatment with topical 5-ASA,  ongoing treatment with Topical 
steroids and ongoing treatment with oral steroids. 
Abbreviations: 5-ASA, 5-aminosalycilic acid; ADA, adalimumab; Anti-TNF, anti-tumor necrosis factor alpha monoclonal 
antibodies; CI, confidence interval; GOL, golimumab; IFX, infliximab; IV, intravenous; OR, odds ratio; SC, subcutaneous.  
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Table 3: Adverse events in patients with ulcerative proctitis treated with anti-TNF 
 n=104 
Infusion reaction 3 
Skin lesions 5 
Alopecia 1 
Infections 4 
Arthralgia 4 
Delayed hypersensitivity  1 
Headache 1 
Abnormal liver enzymes 1 
Weight gain 1 
Muscle weakness 1 
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Figure 1: Efficacy of anti-TNFα therapy in patients with refractory ulcerative proctitis.  
Figure 2: Sustained clinical remission during follow-up in patients with ulcerative proctitis 
treated with anti-TNF. a, proportion of patients with sustained clinical remission during 
follow-up in the overall population (n=104). b, proportion of patients with sustained clinical 
remission during follow-up among anti-TNFα primary responders (n=80).  
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WHAT YOU NEED TO KNOW 
Background: 
• Management of refractory ulcerative proctitis is challenging as patients with 
ulcerative colitis limited to the rectum are systematically excluded from randomized 
clinical trials investigating efficacy of biologics.  
• We investigated the effectiveness of tumor necrosis factor (TNF) antagonists in a 
large cohort of patients with refractory ulcerative proctitis. 
Findings: 
• In a retrospective study of 104 patients with refractory ulcerative proctitis, anti-TNF 
therapy induced clinical remission in 50% and mucosal healing in 60%.  
• About two thirds of the patients were still receiving anti-TNF therapy at 2 years. 
Implications for patient care: 
• Anti-TNF agents might be a good therapeutic option for patients with ulcerative 
proctitis. 
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Supplementary Table 1: Changes in biological and endoscopic parameters with anti-TNF 
therapy 
Biological parameter Baseline At 3 months p-value 
Mean CRP level (mg/l, n=49) 11.6 ± 21.4 4.7 ± 4.6 0.028 
Endoscopic parameters* Baseline Follow-up p-value 
Mayo endoscopic subscore (from 0 to 3, n=46) 2.4 ± 0.6 1.3 ± 1.1 < 0.001 
UCEIS index (from 0 to 8, n=42) 4.9 ± 1.4 2.3 ± 2.3 < 0.001 
*Follow-up colonoscopies were performed after a median delay from anti-TNF initiation of 11.7 (IQR: 
5.5 - 17.4) months. 
Abbreviations: Anti-TNF, anti-tumor necrosis factor alpha monoclonal antibodies; CRP, C reactive 
protein; IQR, interquartile range; n, number of patients; UCEIS, ulcerative colitis endoscopic index of 
severity;  
